Details of the Drug Combination

General Information of Drug Combination (ID: DCFHK26)

Drug Combination Name
Arfolitixorin SY-1425
Indication
Disease Entry Status REF
Mixed endometrioid and clear cell carcinoma Investigative [1]
Component Drugs Arfolitixorin   DMIXMYK SY-1425   DMH8UF0
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: IGROV1
Zero Interaction Potency (ZIP) Score: 6.46
Bliss Independence Score: 3.38
Loewe Additivity Score: 7.43
LHighest Single Agent (HSA) Score: 5.73

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Arfolitixorin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [3]
Myelodysplastic syndrome 2A37 Phase 1 [3]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [3]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)